Evvy
Precision Women’s Healthcare Platform
Evvy is unlocking precision female healthcare through researching female biomarkers, starting with the vaginal microbiome.
Vaginal discomfort is one of the leading reasons women seek healthcare advice—for bacterial vaginosis (BV), yeast infections, urinary tract infections (UTIs), etc.—and over 90% of these cases can be attributed to imbalances in the vaginal microbiome. Unfortunately, patients seeking care for vaginal health are more likely to be misdiagnosed than correctly diagnosed and more likely to have their infection recur than resolve.
What’s more, the latest research has revealed groundbreaking links between the vaginal microbiome and female health outcomes such as infertility, sexually transmitted infections (STIs), preterm birth, gynecologic cancers, and more.
Evvy is pioneering a new standard for vaginal healthcare. They launched the world’s first and only CLIA-certified metagenomic vaginal microbiome test, providing patients with a comprehensive understanding of all bacteria and fungi in their microbiome with one at-home swab. Insights from Evvy’s test led to the expansion of their innovative vaginal health platform, which now brings together state-of-the-art testing, precision clinical care and prescription treatment, and 1:1 coaching. In September 2023, Evvy continued the expansion of their service to include an Expanded PCR Panel, which adds STI testing, antibiotic resistance reports, and one- to three-day expedited turnaround for preliminary results (all using the same swab).
To date, Evvy has served over 25,000 patients with precision vaginal healthcare. The company recently closed a $14 million Series A and plans to further scale access to its innovative testing and care platform, leverage AI to discover novel molecular signatures for women’s health diagnostics, and validate improved outcomes in additional indication areas.
